We demonstrated that the Proseek assay panels provide similar results to conventional assays for CA125 and can be used to identify new candidate biomarkers that, when combined with CA125, can improve the detection of ovarian cancer over using CA125 alone. This evidence concerns the gene MUC16 and ovarian carcinoma.